TABLE 2

Growth Velocity During the Entire Study Period (mITT)

TreatmentRun-in Period, cm/yDouble-Blind Treatment Period, cm/yDifference Versus Placebo During Double-Blind Treatment Period, cm/yFollow-up Period, cm/yaDouble-Blind Treatment Period and Follow-up Period Combined, cm/y
CIC40 (n = 206)
    Mean ± SE6.59 ± 0.095.73 ± 0.08−0.02 ± 0.096.06 ± 0.305.81 ± 0.08
    95% CI5.57 to 5.89−0.19 to 0.165.65 to 5.97
CIC160 (n = 202)
    Mean ± SE6.20 ± 0.115.60 ± 0.08−0.15 ± 0.095.64 ± 0.245.63 ± 0.09
    95% CI5.44 to 5.76−0.33 to 0.035.46 to 5.80
Placebo (n = 201)
    Mean ± SE6.49 ± 0.105.75 ± 0.085.75 ± 0.235.78 ± 0.08
    95% CI5.59 to 5.905.62 to 5.94
  • a The growth velocity for the follow-up period was based on 2 stadiometric height measurements (months 12 and 14) for most patients (CIC40: n = 187; CIC160: n = 189; placebo: n = 190), per protocol design.